Literature DB >> 16517422

Function of PPARgamma and its ligands in lung cancer.

Ming-Yue Li1, Tak W Lee, Anthony P C Yim, George G Chen.   

Abstract

Peroxisome proliferator-activated receptors gamma (PPAR?) is a transcriptional factor belonging to the ligand-activated nuclear receptor superfamily. PPAR? is highly expressed in adipose tissue and has a dominant regulatory role in adipocyte differentiation. In humans, PPAR? is expressed in multiple tissues such as the breast, colon, lung, ovary, and placenta. In addition to adipogenic and anti-inflammatory effects, PPAR? activation has been shown to be anti-proliferative by virtue of its differentiation-promoting effect, suggesting that activation of PPAR? may be useful in slowing or arresting the proliferation of de-differentiated tumor cells. A number of PPAR? ligands, such as natural prostaglandins and synthetic anti-diabetic thiazolidinediones (TZDs), have been identified. The discovery of PPAR? agonists has enabled the elucidation of the mechanisms involved in the multiple effects of PPAR? on the inhibition of tumor cell growth. The importance of this transcription factor in physiology and pathophysiology has stimulated much research in this field. This review describes structural features of PPAR?, mechanisms of PPAR? gene transcription, and recent developments in the discovery of its biological functions on growth inhibition of lung tumors. Prospects for future research leading to new therapies for lung cancer are also discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517422     DOI: 10.1080/10408360600552587

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  11 in total

1.  The metabolism of proline as microenvironmental stress substrate.

Authors:  James M Phang; Jui Pandhare; Yongmin Liu
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

Review 2.  Behavioral and neurochemical effects of proline.

Authors:  Angela T S Wyse; Carlos Alexandre Netto
Journal:  Metab Brain Dis       Date:  2011-06-04       Impact factor: 3.584

3.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

4.  Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.

Authors:  Saswati Hazra; Steven M Dubinett
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2007-08-13       Impact factor: 4.006

5.  Epigenetic effects and molecular mechanisms of tumorigenesis induced by cigarette smoke: an overview.

Authors:  Rong-Jane Chen; Louis W Chang; Pinpin Lin; Ying-Jan Wang
Journal:  J Oncol       Date:  2011-03-22       Impact factor: 4.375

6.  Involvement of PPARs in Cell Proliferation and Apoptosis in Human Colon Cancer Specimens and in Normal and Cancer Cell Lines.

Authors:  G Martinasso; M Oraldi; A Trombetta; M Maggiora; O Bertetto; R A Canuto; G Muzio
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

7.  A Role for the PPARgamma in Cancer Therapy.

Authors:  Moray J Campbell; Carsten Carlberg; H Phillip Koeffler
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

8.  Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.

Authors:  Sakshi Sikka; Luxi Chen; Gautam Sethi; Alan Prem Kumar
Journal:  PPAR Res       Date:  2012-11-14       Impact factor: 4.964

9.  Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.

Authors:  Maria E Ramos-Nino; Charles D MacLean; Benjamin Littenberg
Journal:  BMC Med       Date:  2007-06-21       Impact factor: 8.775

Review 10.  PPARγ as a Novel Therapeutic Target in Lung Cancer.

Authors:  Aravind T Reddy; Sowmya P Lakshmi; Raju C Reddy
Journal:  PPAR Res       Date:  2016-09-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.